NFE2, nuclear factor, erythroid 2, 4778

N. diseases: 57; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia 		0.060 Biomarker disease BEFREE Retroviral insertional activation of Fli-1 and Spi-1/PU.1, as well as loss of tumour suppressor genes such as p53 or p45 NFE2 have been shown to be critical for the induction and progression of Friend virus-induced erythroleukemias. 12894591 2003
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia 		0.060 Biomarker disease BEFREE Using a chromatin immunoprecipitation assay, we provide evidence for NF-E2 binding directly and specifically to HS2 in living erythroleukemia cells and in mouse fetal liver. 10891470 2000
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia 		0.060 Biomarker disease BEFREE This site is occupied by transcription factors USF1, USF2, EGR1, MafK, and NF-E2 in the human erythroleukemia cell line K562 and exhibits histone modifications typical for enhancers. 30012865 2018
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia 		0.060 AlteredExpression disease BEFREE JNK-mediated turnover and stabilization of the transcription factor p45/NF-E2 during differentiation of murine erythroleukemia cells. 19966288 2010
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia 		0.060 Biomarker disease BEFREE The mechanism of NF-E2-mediated chromatin modification was investigated by complementation analysis in NF-E2-null CB3 erythroleukemia cells. 14597626 2004
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia 		0.060 AlteredExpression disease BEFREE This analysis indicates that binding sites for the hematopoietic transcription factors NF-E2 and GATA-1 are required for the formation of the characteristic chromatin structure of the HS following stable transfection into murine erythroleukemia cells. 7828582 1995
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.010 AlteredExpression disease BEFREE Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. 30755419 2019
CUI: C2347748
Disease: Adult Erythroleukemia
Adult Erythroleukemia 		0.050 Biomarker disease BEFREE Using a chromatin immunoprecipitation assay, we provide evidence for NF-E2 binding directly and specifically to HS2 in living erythroleukemia cells and in mouse fetal liver. 10891470 2000
CUI: C2347748
Disease: Adult Erythroleukemia
Adult Erythroleukemia 		0.050 AlteredExpression disease BEFREE This analysis indicates that binding sites for the hematopoietic transcription factors NF-E2 and GATA-1 are required for the formation of the characteristic chromatin structure of the HS following stable transfection into murine erythroleukemia cells. 7828582 1995
CUI: C2347748
Disease: Adult Erythroleukemia
Adult Erythroleukemia 		0.050 Biomarker disease BEFREE This site is occupied by transcription factors USF1, USF2, EGR1, MafK, and NF-E2 in the human erythroleukemia cell line K562 and exhibits histone modifications typical for enhancers. 30012865 2018
CUI: C2347748
Disease: Adult Erythroleukemia
Adult Erythroleukemia 		0.050 Biomarker disease BEFREE The mechanism of NF-E2-mediated chromatin modification was investigated by complementation analysis in NF-E2-null CB3 erythroleukemia cells. 14597626 2004
CUI: C2347748
Disease: Adult Erythroleukemia
Adult Erythroleukemia 		0.050 AlteredExpression disease BEFREE JNK-mediated turnover and stabilization of the transcription factor p45/NF-E2 during differentiation of murine erythroleukemia cells. 19966288 2010
CUI: C0023896
Disease: Alcoholic Liver Diseases
Alcoholic Liver Diseases 		0.010 Biomarker group BEFREE Moreover, the frequency of C2 allele of cytochrome P45 02E1 was found to be higher in patients with nonfibrotic alcoholic liver disease than in patients with severe hepatic fibrosis or liver cirrhosis. 9211568 1997
CUI: C0332853
Disease: Anastomosis
Anastomosis 		0.010 Biomarker disease BEFREE Retinal flatmounts showed poor peripheral vascularization in Avastin-treated and fellow eyes at P23, with numerous punctate hemorrhages and dilated, tortuous vessels with anastomoses at P45 in the rats exposed to IH. 28770109 2017
CUI: C0002871
Disease: Anemia
Anemia 		0.010 AlteredExpression disease BEFREE Sustained overexpression of NF-E2 in this model induced myeloid expansion with anemia, leukocytosis and thrombocytosis. 23932394 2014
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.010 Biomarker disease BEFREE Immunization with native p45 and p210 reduced atherosclerosis by 66% (P < 0.02) and 59% (P = 0.06), respectively. 18783480 2008
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.010 Biomarker disease BEFREE Immunization with native p45 and p210 reduced atherosclerosis by 66% (P < 0.02) and 59% (P = 0.06), respectively. 18783480 2008
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 AlteredExpression phenotype BEFREE It has been reported that activation of NF-E2 p45-related factor-2 (NRF2), a transcription factor, induces a variety of antioxidant enzymes, and plays an important role in preventing carcinogenesis. 31777421 2019
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.010 Biomarker disease BEFREE Induction of Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) has been demonstrated to be involved in cisplatin resistance in ovarian cancer. 29212168 2017
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.070 AlteredExpression disease BEFREE In murine models, elevated NFE2 levels cause an MPN phenotype with spontaneous leukemic transformation. 29519804 2018
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.070 AlteredExpression disease BEFREE We report that RUNX1 and NF-E2 overexpression is not specific for MPN; these transcripts were also significantly elevated in polycythemias with augmented hypoxia-inducible factor activity whose erythroid progenitors were hypersensitive to EPO. 24297870 2014
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.070 Biomarker disease BEFREE These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies. 22231305 2012
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.070 AlteredExpression disease BEFREE Our data underscore the role of increased NF-E2 activity in the pathophysiology of MPNs. 23589569 2013
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.070 Biomarker disease BEFREE Results of NFE2 and calreticulin immunohistochemistry of MPN TMAs are consistent with previously published data. 27544663 2017
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.070 Biomarker disease BEFREE Modulation by GVS of NFE2 was also observed in freshly isolated CD34(+) cells from MPN patients, and was accompanied by inhibition of their proliferation and differentiation toward the erythroid lineage. 22579713 2012